研究業績

学術論文業績
1. Saitoh K*, Kon S*#, Nakatsuru T, Inui K, Ihara T, Matsumoto N, Kitai Y, Muromoto R, Matsuda T#. Anti-IL-17A blocking antibody reduces cyclosporinA-induced relapse in experimental autoimmune encephalomyelitis mice. Biochemistry and Biophysics Reports. 8:139-145, 2016. *equal contribution. #Corresponding author.

2. Togi S, Muromoto R, Hirashima K, Kitai Y, Okayama T, Ikeda O, Matsumoto N, Kon S, Sekine Y, Oritani K, Matsuda T. A New STAT3-binding Partner, ARL3, Enhances the Phosphorylation and Nuclear Accumulation of STAT3. J Biol Chem. 291:11161-71, 2016.

3. Matsui Y, Kon S, Funakoshi T, Miyashita T, Matsuda T, Iwasaki N. Increased expression of αv integrin as a regulator of fibrosis in Dupuytren's nodules. J Hand Surg Eur Vol. 2016 Mar 11. pii: 1753193416635489. [Epub ahead of print]

4. Muromoto R, Hirao T, Tawa K, Hirashima K, Kon S, Kitai Y, Matsuda T. IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes. Int Immunol. 28:443-52, 2016.

5. Togi S, Hatano Y, Muromoto R, Kawanishi E, Ikeda O, Hirashima K, Kon S, Kitai Y, Yasui T, Oritani K, Matsuda T. Caspase-dependent cleavage regulates protein levels of Epstein-Barr virus-derived latent membrane protein 1. FEBS Lett. 590:808-18, 2016

6. Takahashi A, Kuroki K, Okabe Y, Kasai Y, Matsumoto N, Yamada C, Takai T, Ose T, Kon S, Matsuda T, Maenaka K. The immunosuppressive effect of domain-deleted dimer of HLA-G2 isoform in collagen-induced arthritis mice. Hum Immunol. 77:754-9, 2016.

7. Matsuda T, Muromoto R, Sekine Y, Togi S, Kitai Y, Kon S, Oritani K. Signal transducer and activator of transcription 3 regulation by novel binding partners. World J Biol Chem. 6:324-32, 2015. Review.

8. Kubo K, Iwakami M, Muromoto R, Inagaki T, Kitai Y, Kon S, Sekine Y, Oritani K, Matsuda T. CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells. Biochem Biophys Res Commun. 463:825-31, 2015.

9. Togi S, Nakasuji M, Muromoto R, Ikeda O, Okabe K, Kitai Y, Kon S, Oritani K, Matsuda T. Kaposi's sarcoma-associated herpesvirus-encoded LANA associates with glucocorticoid receptor and enhances its transcriptional activities. Biochem Biophys Res Commun. 463:395-400, 2015

10. Sekine Y, Togi S, Muromoto R, Kon S, Kitai Y, Yoshimura A, Oritani K, Matsuda T.
STAP-2 expression in B16F10 melanoma cells positively regulates protein levels of tyrosinase, which determines organs to infiltrate in the body. J Biol Chem. 290:17462-73, 2015.

11. Endo T, Ito K, Morimoto J, Kanayama M, Ota D, Ikesue M, Kon S, Takahashi D, Onodera T, Iwasaki N, Uede T. Syndecan-4 regulates the development of autoimmune arthritis by modulating B cell migration and germinal center formation. Arthritis Rheumatol. 67:2512-22, 2015.

12. Kato M, Muromoto R, Togi S, Iwakami M, Kitai Y, Kon S, Oritani K, Matsuda T. PML suppresses IL-6-induced STAT3 activation by interfering with STAT3 and HDAC3 interaction. Biochem Biophys Res Commun. 461:366-71, 2015.

13. Kon S#, Nakayama Y, Matsumoto N, Ito K, Kanayama M, Kimura C, Kouro H, Ashitomi D, Matsuda T, Uede T#. A novel cryptic binding motif, LRSKSRSFQVSDEQY, in the C-terminal fragment of MMP-3/7-cleaved osteopontin as a novel ligand for α9β1 integrin is involved in the anti-type II collagen antibody-induced arthritis. PLoS One. 9: e116210, 2014. #Corresponding author.

14. Kouro H*, Kon S*#, Matsumoto N, Miyashita T, Kakuchi A, Ashitomi D, Saito K, Nakatsuru T, Togi S, Muromoto R, Matsuda T#. The novel α4B murine α4 integrin splicing variant inhibits α4-dependent cell adhesion. J Biol Chem. 289:16389-16398, 2014. *equal contribution. #Corresponding author.

15. Fujita N, Oritani K, Ichii M, Yokota T, Saitoh N, Okuzaki D, Sekine Y, Kon S, Muromoto R, Saitoh K, Yoshimura A, Matsuda T, Kanakura Y. Signal-transducing adaptor protein-2 regulates macrophage migration into inflammatory sites during dextran sodium sulfate induced colitis. Eur J Immunol. 44:1791-801, 2014.

16. Sekine Y, Nishida K, Yamasaki S, Muromoto R, Kon S, Kashiwakura J, Saitoh K, Togi S, Yoshimura A, Oritani K, Matsuda T. Signal-Transducing Adaptor Protein-2 Controls the IgE-Mediated, Mast Cell-Mediated Anaphylactic Responses. J Immunol. 192:3488-95, 2014.

17. Ishizaki M, Muromoto R, Akimoto T, Sekine Y, Kon S, Diwan M, Maeda, H, Togi S, Shimoda K, Oritani K, Matsuda T. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int. Immunol. 26:257-67, 2014.

18. Asano T, Iwasaki N, Kon S, Kanayama M, Morimoto J, Minami A, Uede T. α9β1 integrin acts as a critical intrinsic regulator of human rheumatoid arthritis. Rheumatology (Oxford). 53:415-24, 2014.

19. Muromoto R, Nakajima M, Hirashima K, Hirao T, Kon S, Shimoda K, Oritani K, Matsuda T. Jun activation domain-binding protein 1 (JAB1) is required for the optimal response to interferons. J Biol Chem. 288:30969-79, 2013.

20. Togi S, Shiga K, Muromoto R, Kato M, Souma Y, Sekine Y, Kon S, Oritani K, Matsuda T. Y14 positively regulates TNF-a-induced NF-kB transcriptional activity via interacting RIP1 and TRADD beyond an exon-junction complex protein. J Immunol. 191:1436-1444, 2013.

21. Sekine Y, Yamamoto C, Kakisaka M, Muromoto R, Kon S, Ashitomi D, Fujita N, Yoshimura A, Oritani K, Matsuda T. Signal-transducing adaptor protein-2 modulates Fas-mediated T cell apoptosis by interacting with Caspase-8. J Immunol. 188:6194-204, 2012.

22. Fujita N, Fujita S, Ogata N, Matsuoka M, Okada Y, Kon S, Uede T, Saika S. Endogenous osteopontin involvement in laser-induced choroidal neovascularization in mice. Invest Ophthalmol Vis Sci. 52:9310-5, 2011

23. Hamamoto S, Yasui T, Okada A, Hirose M, Matsui Y, Kon S, Sakai F, Kojima Y, Hayashi Y, Tozawa K, Uede T, Kohri K. Crucial role of the cryptic epitope SLAYGLR within osteopontin in renal crystal formation of mice. J Bone Miner Res. 26:2967-77, 2011.

24. Kon S, Atakilit A, Sheppard D. Short form of α9 promotes α9β1 integrin-dependent cell adhesion by modulating the function of the full-length α9 subunit. Exp Cell Res. 317:1774-84, 2011.

25. Kurotaki D, Kon S, Bae K, Ito K, Matsui Y, Nakayama Y, Kanayama M, Kimura C, Narita Y, Nishimura T, Iwabuchi K, Mack M, van Rooijen N, Sakaguchi S, Uede T, Morimoto J. CSF-1-Dependent Red Pulp Macrophages Regulate CD4 T Cell Responses. J Immunol. 186:2229-37, 2011.

26. Ohno K, Nishimori H, Yasoshima T, Kamiguchi K, Hata F, Fukui R, Okuya K, Kimura Y, Denno R, Kon S, Uede T, Sato N, Hirata K. Inhibition of osteopontin reduces liver metastasis of human pancreatic cancer xenografts injected into the spleen in a mouse model. Surg Today. 40:347-56, 2010.

27. Nakayama Y, Kon S, Kurotaki D, Morimoto J, Matsui Y, Uede T. Blockade of interaction of alpha9 integrin with its ligands hinders the formation of granulation in cutaneous wound healing. Lab Invest. 90:881-94, 2010.

28. Morimoto J, Kon S, Matsui Y, Uede T. Osteopontin; As a Target Molecule for the Treatment of Inflammatory Diseases. Curr Drug Targets. 11:494-505, 2010.

29. Yamaguchi Y, Hanashima S, Yagi H, Takahashi Y, Sasakawa H, Kurimoto E, Iguchi T, Kon S, Uede T, Kato K. NMR characterization of intramolecular interaction of osteopontin, an intrinsically disordered protein with cryptic integrin-binding motifs. Biochem Biophys Res Commun. 393:487-91, 2010.

30. Seier AM, Renkl AC, Schulz G, Uebele T, Sindrilaru A, Iben S, Liaw L, Kon S, Uede T, Weiss JM. Antigen-specific induction of osteopontin contributes to the chronification of allergic contact dermatitis. Am J Pathol. 176:246-58, 2010.

31. Kurokawa M, Konno S, Takahashi A, Plunkett B, Rittling SR, Matsui Y, Kon S, Morimoto J, Uede T, Matsukura S, Kokubu F, Adachi M, Nishimura M, Huang SK. Regulatory role of DC-derived osteopontin in systemic allergen sensitization. Eur J Immunol. 39:3323-30, 2009.

32. Iwata D, Kitamura M, Kitaichi N, Saito Y, Kon S, Namba K, Morimoto J, Ebihara A, Kitamei H, Yoshida K, Ishida S, Ohno S, Uede T, Onoé K, Iwabuchi K. Prevention of experimental autoimmune uveoretinitis by blockade of osteopontin with small interfering RNA. Exp Eye Res. 90:41-8, 2010.

33. Fujita N, Fujita S, Okada Y, Fujita K, Kitano A, Yamanaka O, Miyamoto T, Kon S, Uede T, Rittling SR, Denhardt DT, Saika S. Impaired angiogenic response in the cornea of mice lacking osteopontin. Invest Ophthalmol Vis Sci. 51:790-4, 2010.

34. Matsui Y, Iwasaki N, Kon S, Takahashi D, Morimoto J, Matsui Y, Denhardt DT, Rittling S, Minami A, Uede T. Accelerated development of aging-associated and instability-induced osteoarthritis in osteopontin-deficient mice. Arthritis Rheum. 60:2362-2371, 2009.

35. Takahashi D, Iwasaki N, Kon S, Matsui Y, Majima T, Minami A, Uede T. Down-regulation of cathepsin K in synovium leads to progression of osteoarthritis in rabbits. Arthritis Rheum. 60:2372-2380, 2009.

36. Kanayama M, Kurotaki D, Morimoto J, Asano T, Matsui Y, Nakayama Y, Saito Y, Ito K, Kimura C, Iwasaki N, Suzuki K, Harada T, Li HM, Uehara J, Miyazaki T, Minami A, Kon S, Uede T. Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol. 182:8015-25, 2009.

37. Takahashi A, Kurokawa M, Konno S, Ito K, Kon S, Ashino S, Nishimura T, Uede T, Hizawa N, Huang SK, Nishimura M. Osteopontin is involved in migration of eosinophils in asthma. Clin Exp Allergy. 39:1152-9, 2009.

38. Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW, Chambers AF. New Dual Monoclonal ELISA for Measuring Plasma Osteopontin as a Biomarker Associated with Survival in Prostate Cancer: Clinical Validation and Comparison of Multiple ELISAs. Clin Chem. 55:895-903, 2009.

39. Ito K, Kon S, Nakayama Y, Kurotaki D, Saito Y, Kanayama M, Kimura C, Diao H, Morimoto J, Matsui Y, Uede T. The differential amino acid requirement within osteopontin in alpha4 and alpha9 integrin-mediated cell binding and migration. Matrix Biol. 28:11-9, 2009.

40. Diao H, Iwabuchi K, Li L, Onoe K, Kaer LV, Kon S, Saito Y, Morimoto J, Denhardt DT, Rittling S, Uede T. Osteopontin regulates development and function of invariant natural killer T cells. Proc Natl Acad Sci U S A. 105:15884-9, 2008.

41. Miyazaki K, Okada Y, Yamanaka O, Kitano A, Ikeda K, Kon S, Uede T, Rittling SR, Denhardt DT, Kao WW, Saika S. Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci. 49:1367-75, 2008.

42. Nagasaka A, Matsue H, Matsushima H, Aoki R, Nakamura Y, Kambe N, Kon S, Uede T, Shimada S. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol. 38:489-99, 2008.

43. Kon S, Ikesue M, Kimura C, Aoki M, Nakayama Y, Saito Y, Kurotaki D, Diao H, Matsui Y, Segawa T, Maeda M, Kojima T, Uede T. Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J Exp Med. 205:25-33, 2008.

44. Saito Y*, Kon S*, Fujiwara Y, Nakayama Y, Kurotaki D, Fukuda N, Kimura C, Kanayama M, Ito K, Diao H, Matsui Y, Komatsu Y, Ohtsuka E, Uede T. Osteopontin small interfering RNA protects mice from fulminant hepatitis. Hum Gene Ther. 18:1205-14, 2007. *equal contribution.

45. Yamamoto N, Nakashima T, Torikai M, Naruse T, Morimoto J, Kon S, Sakai F, Uede T. Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. Int Immunopharmacol. 7:1460-70, 2007.

46. Kitamura M, Iwabuchi K, Kitaichi N, Kon S, Kitamei H, Namba K, Yoshida K, Denhardt DT, Rittling SR, Ohno S, Uede T, Onoe K. Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J Immunol. 178:6567-72, 2007.

47. Nakaishi M, Kajino K, Ikesue M, Hagiwara Y, Kuwahara M, Mitani H, Horikoshi-Sakuraba Y, Segawa T, Kon S, Maeda M, Wang T, Abe M, Yokoyama M, Hino O. Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin. Cancer Sci. 98:659-64, 2007.

48. Begum MD, Umemura M, Kon S, Yahagi A, Hamada S, Oshiro K, Gotoh K, Nishizono A, Uede T, Matsuzaki G. Suppression of the bacterial antigen-specific T cell response and the dendritic cell migration to the lymph nodes by osteopontin. Microbiol Immunol. 51:135-47, 2007.

49. Saika S, Shirai K, Yamanaka O, Miyazaki KI, Okada Y, Kitano A, Flanders KC, Kon S, Uede T, Kao WW, Rittling SR, Denhardt DT, Ohnishi Y. Loss of osteopontin perturbs the epithelial-mesenchymal transition in an injured mouse lens epithelium. Lab Invest. 87:130-8, 2007.

50. Mori N, Majima T, Iwasaki N, Kon S, Miyakawa K, Kimura C, Tanaka K, Denhardt DT, Rittling S, Minami A, Uede T. The role of osteopontin in tendon tissue remodeling after denervation-induced mechanical stress deprivation. Matrix Biol. 26:42-53, 2007.

51. Yasen M, Kajino K, Kano S, Tobita H, Yamamoto J, Uchiumi T, Kon S, Maeda M, Obulhasim G, Arii S, Hino O. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res. 11:7354-61, 2005.

52. Inomata S, Shijubo N, Kon S, Maeda M, Yamada G, Sato N, Abe S, Uede T. Circulating interleukin-18 and osteopontin are useful to evaluate disease activity in patients with tuberculosis. Cytokine. 30:203-11, 2005.

53. Renkl AC, Wussler J, Ahrens T, Thoma K, Kon S, Uede T, Martin SF, Simon JC, Weiss JM. Osteopontin functionally activates dendritic cells and induces their differentiation towards a Th-1 polarizing phenotype. Blood. 106:946-55, 2005.

54. Kadota J, Mizunoe S, Mito K, Mukae H, Yoshioka S, Kawakami K, Koguchi Y, Fukushima K, Kon S, Kohno S, Saito A, Uede T, Nasu M. High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir Med. 99:111-7, 2005.

55. Watanabe K, Saito K, Kinjo M, Matsuda T, Tamura M, Kon S, Miyazaki T, Uede T. Molecular dynamics of STAT3 on IL-6 signaling pathway in living cells. Biochem Biophys Res Commun. 324:1264-73, 2004.

56. Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D, Segawa T, Maeda M, Hamuro J, Nakayama T, Taniguchi M, Yagita H, Van Kaer L, Onoe K, Denhardt DT, Rittling S, Uede T. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity. 21:539-50, 2004.

57. Miyazaki T, Shen M, Fujikura D, Tosa N, Kon S, Uede T, Reed JC. Functional role of death associated protein 3 (DAP3) in anoikis. J Biol Chem. 279:44667-72, 2004.

58. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, Liu L, Morimoto J, Rittling SR, Denhardt D, Kitabatake A, Uede T. Role of Osteopontin in Cardiac Fibrosis and Remodeling in Angiotensin II-Induced Cardiac Hypertrophy. Hypertension. 43:1195-201, 2004.

59. Adachi H, Majima S, Kon S, Kobayashi T, Kajino K, Mitani H, Hirayama Y, Shiina H, Igawa M, Hino O. Niban gene is commonly expressed in the renal tumors: a new candidate marker for renal carcinogenesis. Oncogene. 23:3495-3500, 2004.

60. Yasumi T, Katamura K, Yoshioka T, Meguro TA, Nishikomori R, Heike T, Inobe M, Kon S, Uede T, Nakahata T. Differential requirement for the CD40-CD154 costimulatory pathway during Th cell priming by CD8 alpha+ and CD8 alpha- murine dendritic cell subsets. J Immunol. 172:4826-33, 2004.

61. Morimoto J, Inobe M, Kimura C, Kon S, Diao H, Aoki M, Miyazaki T, Denhardt DT, Rittling S, Uede T. Osteopontin affects the persistence of beta-glucan-induced hepatic granuloma formation and tissue injury through two distinct mechanism. Int Immunol. 16:477-488, 2004.

62. Tanaka K, Morimoto J, Kon S, Kimura C, Inobe M, Diao H, Hirschfeld G, Weiss JM, Uede T. Effect of osteopontin alleles on beta-glucan induced granuloma formation in the mouse liver. Am J Pathol. 164:567-75, 2004.

63. Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S, Ishida T, Tabunoki Y, Kitayama H, Mizuki M, Katada Y, Asaoku H, Kitano M, Nishimoto N, Yoshizaki K, Maeda M, Kon S, Kinoshita N, Uede T, Kawase I. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol. 123:263-70, 2003.

64. Yamamoto N, Sakai F, Kon S, Morimoto J, Kimura C, Yamazaki H, Okazaki I, Seki N, Fujii T, Uede T. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest. 112:181-8, 2003.

65. Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T, Akino M, Sugawara T, Morimoto J, Kimura C, Kon S, Denhardt D, Kitabatake A, Uede T. Osteopontin Deficiency Attenuates Atherosclerosis in Female Apolipoprotein E-Deficient Mice.
Arterioscler Thromb Vasc Biol. 23:1029-34, 2003.

66. Matsui Y, Okamoto H, Inobe M, Jia N, Shimizu T, Akino M, Sugawara T, Tezuka K, Nakayama Y, Morimoto J, Kimura C, Kon S, Miyazaki T, Kitabatake A, Uede T. Adenovirus-Mediated Gene Transfer of ICOSIg Fusion Protein Ameliorates Ongoing Experimental Autoimmune Myocarditis. Hum Gene Ther. 14:521-32, 2003.

67. Kanaya K, Tsuchida Y, Inobe M, Murakami M, Hirose T, Kon S, Kawaguchi S, Wada T, Yamashita T, Ishii S, Uede T. Combined gene therapy with adenovirus vectors containing CTLA4Ig and CD40Ig prolongs survival of composite tissue allografts in rat model. Transplantation. 75:275-81, 2003.

68. Koguchi Y, Kawakami K, Uezu K, Fukushima K, Kon S, Maeda M, Nakamoto A, Owan I, Kuba M, Kudeken N, Kadota JI, Mukae H, Kohno S, Uede T, Saito A.  High plasma osteopontin level and its relationship with IL-12-mediated Th1 response in tuberculosis.  Am J Respir Crit Care Med. 167:1355-9, 2003.

69. Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, Kobayashi H, Shimizu M, Katada Y, Wakitani S, Murata N, Nomura S, Matsuno H, Katayama R, Kon S, Inobe M, Uede T, Kawase I, Saeki Y. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol. 29:2061-7, 2002.

70. Chiba S, Okamoto H, Kon S, Kimura C, Murakami M, Inobe M, Matsui Y, Sugawara T, Shimizu T, Uede T, Kitabatake A. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels. 16:111-7, 2002.

71. Ohshima S, Kobayashi H, Yamaguchi N, Nishioka K, Umeshita-Sasai M, Mima T, Nomura S, Kon S, Inobe M, Uede T, Saeki Y. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: Possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum. 46:1094-101, 2002.

72. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, Nifuji A, Uede T, Denhardt DT, Noda M. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A. 99:4556-4561, 2002.

73. Koguchi Y, Kawakami K, Kon S, Segawa T, Maeda M, Uede T, Saito A. Penicillium marneffei causes osteopontin-mediated production of interleukin-12 by peripheral blood mononuclear cells. Infect Immun. 70:1042-8, 2002.

74. Kon S, Yokosaki Y, Maeda M, Segawa T, Horikoshi Y, Tsukagoshi H, Rashid MM, Morimoto J, Inobe M, Shijubo N, Chambers AF, Uede T. Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. J Cell Biochem. 84:420-32, 2002.

75. Maeda K, Takahashi K, Takahashi F, Tamura N, Maeda M, Kon S, Uede T, Fukuchi Y. Distinct rolaes of osteopontin fragments in the development of the pulmonary involvement in sarcoidosis. Lung. 179:279-91, 2001.

76. Weiss JM, Renkl AC, Maier CS, Kimmig M, Liaw L, Ahrens T, Kon S, Maeda M, Hotta H, Uede T, Simon JC. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med. 194:1219-29, 2001.

77. Takahashi F, Takahashi K, Okazaki T, Maeda K, Ienaga H, Maeda M, Kon S, Uede T, Fukuchi Y. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 24:264-71, 2001 .

78. Gang X, Ueki K, Kon S, Maeda M, Naruse T, Nojima Y. Reduced urinary excretion of intact osteopontin in patients with IgA nephropathy. Am J Kidney Dis. 37:374-9, 2001.

79. Shijubo N, Uede T, Kon S, Nagata M, Abe S. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog. 11:135-46. Review, 2000.

80. Chiba S, Rashid MM, Okamoto H, Shiraiwa H, Kon S, Maeda M, Murakami M, Inobe M, Kitabatake A, Chambers AF, Uede T. The role of osteopontin in the development of granulomatous lesions in lung. Microbiol Immunol. 44:319-32, 2000.

81. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem. 77:487-98, 2000.

82. Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, Uede T, Matsumoto T, Saito Y, Mori S. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol. 20:624-8, 2000.

83. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M, Abe S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med. 160:1269-73, 1999.

84. Yasui T, Fujita K, Hayashi Y, Ueda K, Kon S, Maeda M, Uede T, Kohri K. Quantification of osteopontin in the urine of healthy and stone-forming men. Urol Res. 27:225-30, 1999.

85. Hotta H, Kon S, Katagiri YU, Tosa N, Tsukamoto T, Chambers AF, Uede T. Detection of various epitopes of murine osteopontin by monoclonal antibodies. Biochem Biophys Res Commun. 257:6-11, 1999.

86. Murakami M, Takahashi Y, Isashi Y, Kon S, Jia WY, Inobe M, Abe R, Uede T. Identification and characterization of an alternative cytotoxic T lymphocyte-associated protein 4 binding molecule on B cells. Proc Natl Acad Sci U S A. 93:7838-42, 1996.
研究助成金 (研究代表者のみ)
平成28年度
1.科学研究費補助金、基盤研究(C) 
2.薬理研究会第18回(平成28年度)研究助成
3.ファイザー・アカデミック・コントリビューション

平成27年度
1.日本リウマチ財団、リウマチ性疾患調査・研究助成
2. 薬学奨励財団 研究助成
3. 中冨健康科学振興財団 研究助成

平成26年度
1.科学研究費補助金、基盤研究(C) (継続)
2. 公益信託医用薬物研究奨励富岳基金

平成25年度
1.科学研究費補助金、基盤研究(C) (継続)
2. ノーステック財団「研究開発助成事業」発展・橋渡し研究補助金
3. 寿原記念財団、研究助成

平成24年度
1.科学研究費補助金、基盤研究(C) 
2.秋山記念生命科学振興財団、研究助成
3. ノーステック財団「研究開発助成事業」スタートアップ研究補助金
4. 鈴木謙三記念医科学応用研究財団、調査研究助成

平成19年度
1. 上原記念生命科学財団、海外留学助成金リサーチフェローシップ

平成16年度
1. 文科省科学研究費補助金、若手研究B(継続)
2. 秋山記念生命科学振興財団、研究助成(奨励)

平成15年度
1.文科省科学研究費補助金、若手研究B
2.伊藤医薬学術交流財団、国際学会等助成
特許出願
1. 【特許出願番号】PCT/JP2012/004191【名称】「可溶性インテグリンα4変異体」【出願日】2012年6月28日

2. 【特許出願番号】特願2008-61069【名称】「ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法」【出願日】2008年3月11日

3. 【特許出願番号】2006-332850【名称】「オステオポンチンsiRNA」【出願日】2006年12月11日

4. 【特許出願番号】P06-0226【名称】「細胞外マトリックスタンパク質のアミノ酸配列RGDに対する抗体およびその製法と用途」【出願日】2006年10月26日

5. 【特許出願番号】P06-0156【名称】「抗ヒトα9インテグリン抗体とその用途」【出願日】2006年7月12日

6. 【特許出願番号】PCT/JP2006/300676【名称】「抗α9インテグリン抗体とその用途」【出願日】2006年1月12日

7. 【特許出願番号】PCT/JP2005/007071【名称】「オステオポンチンsiRNA」【出願日】2005年4月12日

8. 【特許出願番号】2005-006348【名称】「抗9インテグリン抗体」【出願日】平成17年1月13日

9. 【特許出願番号】PCT/JP2004/17168 【名称】「腱・靱帯の劣化予防剤、治療剤」【出願日】2004年11月04日。

10. 【特許出願番号】PCT/JP2004/007321【名称】「免疫担当細胞活性化阻害剤およびその用途」【出願日】2004年5月21日。

11. 【特許公開番号】2005-323591【名称】「オステオポンチンsiRNA」【公開日】平成16年4月12日。

12. 【特許出願番号】2003-146188「肝障害治療薬」

13. 【国際公開番号】WO2003/027151【名称】「組換え抗オステオポンチン抗体およびその用途」【公開日】平成15年4月3日。

14. 【特許公開番号】2003-294735【名称】「結核診断剤およびこれを含有する結核診断用キット」【公開日】平成15年10月15日。

15. 【出願番号】2001-107578【発明の名称】「抗オステオポンチンアイソフォームに対する抗体およびその製造方法並びにこれを利用したオステオポンチンアイソフォームの検出方法」【出願日】平成13年4月5日。

16. 【国際公開番号】 WO2002/081522【発明の名称】「抗オステオポンチン抗体およびその用途」【公開日】平成14年10月17日。
著書、総説
1. 石崎雅之、室本竜太、今 重之、織谷健司、松田 正:乾癬の発症とTYK2。臨床免疫・アレルギー科 61(2):214-220, 2014

2. 松田正、今 重之、室本竜太:分子標的薬-がんから他疾患までの治癒を目指して- JAK/STATシグナル伝達経路を標的とした分子標的薬。日本臨牀70巻、増刊号8、 P45-51, 2012

3. 今 重之:メディカル免疫学(監訳 小野江和則、上出利光)第16章 p151-p160、2006

4. 今 重之、上出利光:オステオポンチンを標的とした関節炎の治療。分子リウマチ 3: 175-181, 2005

5. 上出利光、森本純子、今 重之:B型ウイルス肝炎の分子免疫学。HBV感染と免疫機序。肝炎とOPN (osteopontin)/Eta-1 (early T lymphocyte activation-1)、日本臨牀62巻 増刊号8 P74-78, 2004

6. 今 重之、樋野興夫:組織マイクロアレイ。Medical Technology 30: 759-760, 2002

7. 今 重之、樋野興夫:組織マイクロアレイ法:サンプル調整法とデータの例。ポストゲノム時代の免疫染色・in situハイブリダイゼーション 43-46, 2002

8. 今 重之、樋野興夫:組織マイクロアレイ。Molecular Medicine 38: 825-828, 2001

9. 上出利光、今 重之、堀越優子、前田雅弘、堀田 裕、塚本泰司、片桐洋子:オステオポンチンと疾患。病理と臨床 18: 342-348, 2000

10. 上出利光、今 重之、前田雅弘:肉芽形成とオステオポンチン。臨床免疫34: 91-96, 2000

11. 村上正晃、高橋陽子、今 重之、上出利光:B細胞上CD28/CTLA4結合分子ACBM。Molecular Medicine 34: 106-111, 1997

12. 今 重之、村上正晃:B細胞上に発現するCTLA4結合分子ACBM。臨床免疫。29: 986-993, 1997
新聞掲載
・「がん転移を抑制する新たな細胞接着制御メカニズム」北海道医療新聞 2014年6月27日
・「インテグリン-細胞外マトリックス相互作用を阻害できる医薬の開発」薬事日報2015年6月22日